Skip to content
Open access

A brain-penetrant TRPML1 agonist enhances autophagy–lysosomal function and mitigates pathology in aged models of Parkinson’s and Alzheimer’s diseases

Sep 2026 · Scientific Reports · 0 citations

TL;DR

This work describes LW-1017, a potent, selective, and brain-penetrant small-molecule TRPML1 agonist and evaluates its pharmacodynamic activity and therapeutic effects in aged preclinical mouse models of Parkinson’s disease (PD) and Alzheimer’s disease (AD), supporting TRPML1 agonism as a promising strategy to counteract age-associated neurodegenerative disease.

Abstract

Age-related decline in autophagy–lysosomal pathway function is a key contributor to the accumulation of toxic protein aggregates, neuroinflammation, and neuronal loss in neurodegenerative diseases. Transient receptor potential mucolipin-1 (TRPML1) is a lysosomal Ca²⁺ channel that coordinates acute lysosomal signaling and MiT/TFE-dependent transcription to promote lysosomal biogenesis, cellular clearance, and neuronal resilience. Despite strong mechanistic rationale, whether pharmacological activation of TRPML1 can therapeutically modulate disease-relevant pathology in vivo has remained unresolved. Here, we describe LW-1017, a potent, selective, and brain-penetrant small-molecule TRPML1 agonist and evaluate its pharmacodynamic activity and therapeutic effects in aged preclinical mouse models of Parkinson’s disease (PD) and Alzheimer’s disease (AD). LW-1017 activated TRPML1-mediated ion conductance and induced concentration-dependent nuclear translocation of TFEB/TFE3/MiTF, leading to coordinated activation of CLEAR network genes. In vivo, oral administration achieved robust central nervous system exposure and produced sustained modulation of lysosomal and autophagy biomarkers, including lipidation of LC3 and GABARAPL1 and induction of lysosome-associated proteins. In an aged α-synuclein–based PD model, LW-1017 dose-dependently reduced pathological α-synuclein, attenuated gliosis, preserved nigrostriatal dopaminergic integrity, and improved motor performance. In an aged amyloid-β oligomer model of AD, LW-1017 reduced amyloid and phosphorylated tau pathology, decreased neuroinflammation, preserved neuronal integrity, and improved cognition. Efficacy was observed at low oral doses (3 mg/kg/day), consistent with efficient brain penetration and target engagement. Together, these findings provide the first in vivo evidence that pharmacological activation of TRPML1 can engage autophagy–lysosomal pathways and ameliorate pathology in aged models of both AD and PD, supporting TRPML1 agonism as a promising strategy to counteract age-associated neurodegenerative disease.

Read PDF

Similar papers

Review Open access Sep 2026

HMGB1 in Amyloid-Beta Pathology: Mechanistic Insights and Therapeutic Implications for Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles. Beyond these hallmark pathological features, the complex pathogenesis of AD involves cellular dysfunctions associated with chronic oxidative stress and neuroin...

Song-I. Seol, Ji-Eun Kim, Dashdulam Davaanyam et al. · 0 citations
Oct 2026

Icariin enhances PINK1-associated mitophagy to attenuate NLRP3/GSDMD-related microglial pyroptosis and cognitive impairment in Alzheimer's disease.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which microglia-mediated neuroinflammation contributes to disease progression. Icariin (ICA), a major bioactive flavonoid from Epimedium, has neuroprotective activity, but how it regulates mitochondrial quality control and inflammatory injury in mi...

Long-Min Fan, Hai-Tao Jiang, Min Yi et al. · 0 citations
Open access Sep 2026

MA-5 attenuates disease-associated transcriptomic aging and pathological microglial states in Gaucher disease

Overall, MA-5 suppresses neuroinflammation and reverses accelerated transcriptomic aging, supporting its potential as a therapeutic strategy for GD and other lysosomal storage disorders, as well as for diseases characterized by mitochondrial dysfunction, chronic inflammation, and pathological accumulation.

Y. Tongu, Tomoko Kasahara, Kohta Nakamura et al. · 0 citations
Open access Sep 2026

Gomisin N ameliorates autophagy-neuroinflammation imbalance in Parkinson's disease models via modulating the ATG16L1/NLRP3 axis.

GN is a brain-penetrant preclinical candidate that links ATG16L1-dependent autophagy with α-synuclein clearance and NLRP3 inflammasome suppression in PD models and completely abrogated the neuroprotective and anti-inflammatory effects of GN both in vitro and in vivo.

Cheng-Fu Su, Zhi-Qiang Deng, Ka-Yee Ying et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.